Key result
Reduced-dose ticagrelor provides comparable platelet inhibition to the standard dose post-AMI.
Why the study?
Ticagrelor maintenance dose reduction 1-3 years post-AMI provides sufficient platelet inhibition and improves safety, but its antiplatelet effect beginning 1 month post-AMI was unknown.
Does a reduced maintenance dose of ticagrelor (60 mg b.i.d) provide comparable platelet inhibition to the standard dose (90 mg b.i.d) in stable patients 1 month after AMI?
RCT (n=52)
Open-label
1:1 ratio
No
Does a reduced maintenance dose of ticagrelor (60 mg b.i.d) provide comparable platelet inhibition to the standard dose (90 mg b.i.d) in stable patients 1 month after AMI?
Absolute Event Rate: 10.4% vs 14.1%
p-value: p=0.30
Lowering the ticagrelor maintenance dose to 60 mg twice daily 1 month after AMI provides comparable platelet inhibition to the standard 90 mg twice daily dose.
No takes yet. Share an insight, caveat, or question.
Supports ticagrelor dose reduction to 60 mg b.i.d. at 1 month post-AMI; extends pharmacodynamic evidence for de-escalation in stable patients.
Kubica et al. (2019) conducted an RCT in Acute myocardial infarction (AMI) (n=52). Ticagrelor vs. Ticagrelor 90 mg b.i.d was evaluated on Platelet inhibition evaluated with the VASP assay (platelet reactivity index) (p=0.30). A reduced maintenance dose of ticagrelor (60 mg b.i.d) provided comparable platelet inhibition to the standard dose (90 mg b.i.d) 45 days post-AMI (VASP index 10.4 vs 14.1; P=0.30).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: